No evidence for squaring the survival curve: lifespan-extending treatments increase variation in age- at-death
Biology Letters · 2026
DOI: 10.1098/rsbl.2025.0651 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biology Letters, 2026. Verfasst von Tahlia L Fulton und 2 weiteren Autor:innen. Beteiligte Einrichtung: Charles Perkins Centre, University of Sydney, Camperdown, NSW2006, Australia. Hauptthemen laut MEDLINE: Longevity, Metformin, Caloric Restriction, Sirolimus. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Sydney, Australian Research Council.
Abstract (Originalsprache)
Geroscience has the goal of extending lifespan through geroprotective interventions. These interventions are typically imparted on groups of individuals, with their efficacy judged by increases in the average age-at-death. A more equitable outcome, which looks beyond the average, is to attain a long life for all individuals, such that the average age-at-death is high while variability (e.g. standard deviation in age-at-death) is low. This goal of increasing the mean while reducing variation is sometimes referred to as ‘squaring the survival curve’. A recent meta-analysis of vertebrate data found that dietary restriction (DR) and the DR-mimetic, rapamycin, generally increase the average age-at-death, while metformin (also considered a DR-mimetic) is less effective. We have re-analysed this recently published data to study the effects of lifespan-extending treatments on variation in the age-at-death. On average, all three treatments increase the variance in the age-at-death, but not the coefficient of variation (i.e. standard deviation relative to the mean). This suggests that lifespan-extending treatments do not reduce variance and ‘square the survival curve’. Rather, any gains in mean age-at-death are matched by corresponding increases in variation. Interestingly, this result is consistent with the treatments proportionally reducing both the age-dependent and age-independent parameters in a Gompertz model of mortality.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Charles Perkins Centre, University of Sydney, Camperdown, NSW2006, Australia.
- School of Life and Environmental Sciences, University of Sydney, Sydney, NSW, Australia.
- Institute of Organismic and Molecular Evolution, Johannes Gutenberg University Mainz, Mainz55122, Germany.
- Evolution and Ecology Research Centre, School of Biological, Earth, and Environmental Sciences, University of New South Wales, Sydney, New South Wales2052, Australia.
- Sydney Precision Data Science Centre, University of Sydney, Camperdown2006, Australia.
ORCID-Profile: Tahlia L Fulton, Erin L Macartney, Alistair M Senior
Förderung
- University of Sydney
- Australian Research Council
Zitieren
APA
Fulton, T. L., Macartney, E. L., & Senior, A. M. (2026). No evidence for squaring the survival curve: lifespan-extending treatments increase variation in age- at-death. Biology Letters. https://doi.org/10.1098/rsbl.2025.0651
Vancouver
Fulton TL, Macartney EL, Senior AM. No evidence for squaring the survival curve: lifespan-extending treatments increase variation in age- at-death. Biology Letters. 2026. doi:10.1098/rsbl.2025.0651
BibTeX
@article{Fulton2026,
author = {Fulton, Tahlia L and Macartney, Erin L and Senior, Alistair M},
title = {No evidence for squaring the survival curve: lifespan-extending treatments increase variation in age- at-death},
journal = {Biology Letters},
year = {2026},
doi = {10.1098/rsbl.2025.0651}
}
EUVIMED